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Insight in hospitalizations in long-term childhood cancer survivors (CCS) is useful to under-
stand the impact of long-term morbidity. We aimed to investigate hospitalization rates and
underlying types of diagnoses in CCS compared to matched controls, and to investigate the
determinants.
Methods
We linked 5,650 five-year CCS from the Dutch nationwide Dutch LATER cohort and
109,605 age- and sex-matched controls to the Dutch Hospital Discharge register, which
contained detailed information on inpatient hospitalizations from 1995–2016. Relative hospi-
talization rates (RHRs) were calculated using a Poisson regression model. Adjusting for
multiple hospitalizations per person via a Poisson model for generalized estimated equa-
tions, we investigated determinants for hospitalizations for all types of underlying diagnoses
among CCS.
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Results
CCS were twice as likely to be hospitalized as reference persons (hospitalization rate 178
and 78 per 1,000 person-years respectively; RHR 2.0, 95% confidence interval (CI) 1.9–
2.2). Although CCS had more hospitalizations for 17 types of underlying diagnoses, they
were especially more likely to be hospitalized for endocrine conditions (RHR: 6.0, 95% CI
4.6–7.7), subsequent neoplasms (RHR: 5.6, 95% CI 4.6–6.7) and symptoms without under-
lying diagnoses (RHR: 5.2, 95% CI 4.6–5.8). For those types of underlying diagnoses,
female sex and radiotherapy were determinants.
Conclusion
This study provides new insights in the high risk of hospitalizations for many types of under-
lying diagnoses in CCS and treatment related determinants. CCS are especially at high risk
for hospitalizations for endocrine conditions, subsequent neoplasms and symptoms without
an underlying diagnosis. This new knowledge is important for survivorship care and to iden-
tify possible preventable hospitalizations among CCS.
Introduction
Survival for childhood cancer has improved significantly over the past decades to about 80%
nowadays. [1] Hence, the vast majority of childhood cancer patients will achieve long term
survival and the number of long-term childhood cancer survivors will increase. Unfortunately,
childhood cancer survivors (CCS) are at risk of developing long-term morbidity, such as sub-
sequent malignancies, organ dysfunction, and endocrine disorders. [2–5] By the age of 50, a
childhood cancer survivor has experienced an average of 4.7 severe health conditions, which is
twice as many as in individuals that did not have cancer as a child. [5]
Insight in hospitalizations is useful to understand the impact of this long-term morbidity in
CCS, because hospitalizations indicate severe morbidity that influence the patient’s daily life as
well as healthcare costs. [6–9] Previous studies show that long-term CCS have a 1.5 to 3-fold
higher rate of hospital admissions as compared to the general population. [10–17] Although
several studies have established risk factors for specific long-term morbidity in CCS, it is
unknown whether the same risk factors apply to the risk of hospitalizations for these type of
conditions.
The aim of this study is to longitudinally evaluate the hospitalization rate and types of
underlying conditions in a Dutch nationwide cohort of CCS, as compared to a matched refer-




We obtained our study population from the national Dutch Childhood Oncology Group—
Long term Effects after Childhood Cancer (Dutch LATER) nationwide cohort, a collaborative
effort of all Dutch pediatric oncology/hematology centers. This cohort includes 6,165 5-year
CCS diagnosed with a malignancy according to the third edition of the International Classifi-
cation of Childhood Cancer [18] before the age of 18 years, between 1/1/1963 and 12/31/2001,
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who were living in the Netherlands at the time of childhood cancer diagnosis and who were
treated in one of the Dutch pediatric oncology/hematology centers. Details on cancer diagno-
sis and treatment schedules were retrospectively obtained from medical records using a stan-
dardized protocol. [19]
Dutch Hospital Discharge register
The Dutch Hospital Discharge Register (Dutch acronym: LBZ) is maintained by Dutch Hospi-
tal Data and comprises data on hospital admission(s) of the Dutch population, from 1995 to
2016. [20] The LBZ contains data on date of admission and discharge, discharge diagnosis clas-
sified according to the International Classification of Diseases version 9 (ICD-9) and version
10 (ICD-10), and type of medical specialists involved. [21] Access to the LBZ is provided by
Statistics Netherlands (Dutch acronym: CBS).
Until 2005, the coverage of the LBZ was > 96.7%. [22] After a slight decline in coverage,
from 2013 onwards nearly all hospitalizations were registered in the LBZ, meaning that data
on the total number of hospitalizations were nearly complete, but in in 5.5–21.4% of the cases,
some of the data in individual hospitalization records were incomplete. In those records, infor-
mation about one of the items for hospitalization was missing, for example discharge diagno-
sis, medical specialist at discharge or area where a person lived at time of hospitalization.
Linkage procedure
A deterministic linkage method was performed as displayed in S1 Fig, using a unique identifier
or a combination of sex, date of birth and postal code, if no identifier was available. CBS anon-
ymized these identifying variables for all CCS into an anonymous unique record identification
number (RIN) and removed all other identifying information. Because RIN was also the iden-
tifying variable in the LBZ, RIN was used to link LBZ data to clinical data. We removed CCS
that had deceased before start of the LBZ from the dataset.
Reference sample
A reference sample of the Dutch general population was obtained from the Municipal Personal
Records Database (Dutch acronym: GBA). For each CCS, a maximum of 20 unique reference
persons were selected with corresponding year of birth and sex. RINs were retrieved from all
reference persons from the GBA and were used to retrieve their data from the LBZ. To deter-
mine start of follow-up, reference persons were assigned the date of diagnosis of their corre-
sponding CCS.
Ethical statement
Dutch law allows the use of Electronic Health Records for research purposes under certain
conditions (Dutch Civil Law, Article 7: 458). According to this legislation, it is not necessary to
obtain informed consent from patients or any form of approval or waiver from a medical eth-
ics committee or institutional review board for this type of observational study that contains
no directly identifiable data. This study was also reviewed by the Institutional Review Board of
the Amsterdam UMC and was exempted from the need of ethical approval.
CBS provides access to the LBZ within a secured environment and ensures privacy protec-
tion by using RINs which prevents the possibility of exposing identity of specific individuals in
the registration. According to Dutch LATER privacy regulations, data from CCS could be used
after anonymizing, and data from CCS who explicitly refused the use of their data for linkage
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purposes were considered not eligible (n = 147). According to CBS confidentiality regulations,
we do not present frequencies of less than 10.
Definition of variables
Outcome of interest was the total number of hospitalizations per survivor from 1995 until
2016, defined as inpatient admissions of any duration. Hospitalizations for giving birth were
excluded, as were outpatient clinic visits. Primary discharge diagnoses were categorized into
organ systems according to the ICD-10 chapters. [23] If no discharge diagnosis was available
from the LBZ, the ICD-10 chapter of the discharge diagnosis was assigned according to the
type of medical specialist involved at discharge, or was categorized as missing when no infor-
mation on type of medical specialist was available.
Time at risk started at five years after the primary cancer diagnosis or January 1, 1995,
whichever came latest. Time at risk ended at date of death, date of emigration or December 31,
2015, whichever came first. Time during hospitalization was not counted as time at risk. CCS
who had a recurrence of their primary childhood cancer beyond their five-year survival date
were assumed to have an increased hospitalization rate due to treatment of their recurrence(s).
Therefore, those CCS and their corresponding reference persons were censored at the date of
recurrence of the childhood cancer, and were excluded if they were censored before start of
follow-up (n = 28 CCS and n = 560 corresponding reference persons). Furthermore, 3,395 ref-
erence persons were excluded because they died or emigrated before 1-1-1995 or before start
of follow-up and therefore did not contribute to time at risk.
Primary childhood cancer diagnosis was categorized into 9 subgroups of which a specifica-
tion is available in S1 Table).
Statistical analysis
Differences in characteristics between CCS and reference persons were assessed using Mann
Whitney U tests when continuous and Pearson Chi squared tests when categorical. Hospitali-
zation rates were calculated during the total time at risk for CCS and their matched reference
persons per 1,000 person years (PY), both overall and per ICD-10 category. The absolute
excess rate (AER) was calculated per 1,000 PY by subtracting the hospitalization rate from the
reference population from the hospitalization rate from CCS. Using a Poisson regression
model, Relative Hospitalization Rates (RHRs) were calculated adjusted for matched cases and
controls and for multiple hospitalizations in one person.
Within the cohort of CCS, a multivariable Poisson regression model was built adjusting for
multiple hospitalizations via Generalized Estimated Equations (GEE) to investigate determi-
nants for hospitalizations. Separate models were executed for all underlying types of diagnoses
except perinatal and congenital conditions, because we assumed that treatment of the primary
childhood cancer did not influence these hospitalizations. In each model we included sex, age at
diagnosis of primary cancer (categorical variable), follow-up time (continuous variable), 6
groups of chemotherapy, 9 locations of radiotherapy and surgery (specification in S1 Table).
Two-sided p-values were reported and those of less than 0.05 were considered statistically signif-




After excluding 208 CCS who died before 1-1-1995, and 28 CCS with a recurrence after five-
year survival date that did not contribute to the time at risk (S1 Fig), a total of 5,650 CCS
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contributed 90,752 years at risk and 109,605 reference persons contributed 1,576,910 years at
risk. The mean time from five year survival to end of follow-up was 17.9 years for CCS (inter-
quartile range (IQR) 12.1–21.0) and 15.7 years for reference persons (IQR 10.1–21.0, Table 1).
Hospitalization rates
A total of 16,141 hospitalizations were identified in CCS, resulting in an average rate of 177.9
hospitalizations per 1,000 PY (S2 Table). The average hospitalization rate in the reference pop-
ulation was 77.7 per 1,000 PY (S2 Table). CCS were hospitalized twice as often as the reference
population (RHR: 2.01, 95% confidence interval (CI) 1.89–2.15, p<0.001, Fig 1, S2 Table). The
AER was 100.18 per 1,000 PY in CCS, meaning that if 10 CCS were followed for one year,
there was one extra hospitalization compared to the reference population. All CCS cancer
diagnosis groups, and in particular bone tumors, central nervous system tumors and soft tissue
sarcoma, were associated with a significantly increased hospitalization rate as compared to the
reference population (Fig 2, S1 Table).
Other tumors comprise (frequency tables are displayed in S1 Table):
• Germ cell tumors, trophoblastic tumors, and neoplasms of gonads (Gonadal carcinomas,
Malignant gonadal germ cell tumors, Malignant extracranial and extragonadal germ cell
tumors, Intracranial and intraspinal germ cell tumors, Other and unspecified malignant
gonadal tumors)
• Other malignant epithelial neoplasms and malignant melanomas (Other and unspecified car-
cinomas, Skin carcinomas, Malignant melanomas, Nasopharyngeal carcinomas, Thyroid carci-
nomas, Adrenocortical carcinomas)
• Langerhans cell histiocytosis
• Hepatic tumors (Hepatic carcinomas, Hepatoblastoma)
• Retinoblastoma
• Other and unspecified malignant neoplasms
Compared to the reference population, CCS had significantly higher hospitalization rates
for 17 out of 18 types of discharge diagnoses (Fig 1, S1 Table). Relative to the reference popula-
tion, CCS were most likely to be hospitalized for endocrine, nutritional and metabolic diseases
(RHR: 5.97, 95% CI 4.61–7.73; Fig 1, S2 Table), including metabolic disorders, disorders of the
adrenal gland, disorders of the thyroid gland, and other endocrine disorders (S3 Table). CCS
were second most likely to be hospitalized for subsequent neoplasms (RHR: 5.59, 95% CI
4.64–6.73; Fig 1, S2 Table), among which were subsequent malignant neoplasms, benign neo-
plasms, carcinoma in situ and neoplasms of uncertain behavior (S3 Table). Symptoms, signs
and abnormal clinical findings not elsewhere classified, i.e. symptoms without an underlying
diagnosis, led to over 5 times as many hospitalizations in CCS as in the reference population
(RHR: 5.15, 95% CI 4.57–5.82, Fig 1, S2 Table) and the AER was 24.45, meaning that if 40 CCS
are followed for one year, there was one extra hospitalization compared to the reference popu-
lation. Diseases of the skin and subcutaneous tissue and diseases of the circulatory system also
had high RHRs (RHR: 2.90, 95% CI 2.01–4.18 and RHR: 2.87, 95% CI 2.41–3.41 respectively,
Fig 1, S2 Table). The three most prevalent conditions of the circulatory system for which CCS
were hospitalized, according to S3 Table, were classified as other forms of heart disease
(including acute rheumatic fever, chronic rheumatic heart disease; n = 110), Other diseases of
veins and lymphatics, and other diseases of circulatory system (n = 79), Cerebrovascular dis-
ease (n = 67).
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Table 1. Patient, cancer and treatment characteristics of study population of five-year childhood cancer survivors and age and sex matched reference population.
CCS study population (n = 5,650) Reference population (n = 109,605)
Patient characteristics
Sex1—n (%)
Male 3,152 55.8% 61,070 55.7%
Female 2,498 44.2% 48,535 44.3%
Year of birth1—n (%)
<1970 589 10.4% 11,752 10.7%
1970–1985 2,748 48.6% 54,128 49.4%
>1985 2,131 37.7% 43,725 39.9%
Tumor and treatment characteristics
Age at diagnosis (in years)2—n (%)
0–4 2,557 45.3% 49,145 44.8%
5–9 1,531 27.1% 29,743 27.1%
10–14 1,203 21.3% 23,489 21.4%
15–17 359 6.4% 7228 6.6%
Period of diagnosis2—n (%)
�1974 343 6.1% 6,843 6.2%
1975–1984 1,353 23.9% 26,878 24.5%
1985–1994 2,055 36.4% 40,172 36.7%
1995–2002 1,899 33.6% 35,712 32.6%
Primary childhood cancer3—n (%)
Leukemia 1,900 33.6% NA
Hodgkin lymphoma 383 6.8% NA
Non-Hodgkin lymphoma 543 9.6% NA
Central nervous system tumors 744 13.2% NA
Bone tumors 332 5.9% NA
Soft tissue sarcomas 406 7.2% NA
Renal tumors 567 10.0% NA
Neuroblastoma 303 5.4% NA
Other4 472 8.4% NA
Treatment modality3—n (%)
Surgery only 568 10.1% NA
Chemotherapy ± surgery 2,839 50.2% NA
Radiotherapy ± surgery 432 7.6% NA
Chemotherapy + Radiotherapy ± surgery 1,765 31.2% NA
No therapy/therapy unknown 46 0.8% NA
Chemotherapy5—n(%)
Anthracyclines 2,605 46.1% NA
Alkylating agents 2,878 50.9% NA
Platinum agents 736 13.0% NA
Vinca alkaloids 4,074 72.1% NA
Antimetabolites 2,618 46.3% NA
Epipodophyllotoxins 1,180 20.9% NA
Radiotherapy—n (%)
Cranial radiotherapy4 1,193 21.1% NA
Radiotherapy to the neck4 218 3.9% NA
Radiotherapy to the spine4 355 6.3% NA
Radiotherapy to the thorax5 351 6.2% NA
(Continued)
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Significantly more CCS than reference persons experienced at least one hospitalization
without an underlying diagnosis (n = 1,188, 21.0% and n = 5,895, 5.4% respectively, p = 0.001;
S5 Table) and 458 CCS (8.1%) experienced two or more. All hospitalizations for symptoms
without an underlying diagnosis were classified into respective organ systems, or were labeled
as “other or unknown” if the discharge diagnosis was unclear. The latter occurred significantly
more often for hospitalizations among CCS than among reference persons (n = 1,863/2,722
(68.4%) hospitalizations and n = 2,058/8,471 (24.3%) hospitalizations respectively, p<0.001, S6
Table).
Table 1. (Continued)
CCS study population (n = 5,650) Reference population (n = 109,605)
Abdominopelvic radiotherapy5 420 7.4% NA
Radiotherapy to the upper extremities6 41 0.7% NA
Radiotherapy to the lower extremities6 73 1.3% NA
Total body irradiation4 200 3.5% NA
Other therapies—n (%)
Hematopoietic stem cell transplantation 213 3.8% NA
Follow-up
Attained age at end of follow-up, in years—n (%)
< 20 752 13.3% 10,728 9.8%
20–30 1,899 33.6% 41,256 37.6%
30–40 1,777 31.5% 34,348 31.3%
40–50 990 17.5% 18,380 16.8%
> 50 232 4.1% 4,893 4.5%
Time since 5-year survival to end of follow-up, in years—n (%)
5–9 846 15.0% 26,885 24.5%
10–14 1,364 24.1% 25,107 22.9%
14–19 1,061 18.8% 18,506 16.9%
20–25 2,379 42.1% 39,107 35.7%
Years at risk (total number of years for each group) 90,752 1,576,910
Abbreviations: CCS: Childhood Cancer Survivors
1 Variables used for matching of CCS to the reference population
2 Age at diagnosis and treatment period were calculated for the reference population using the assigned date of diagnosis from their corresponding CCS
3 Variable options are mutually exclusive
4 Other tumors comprise (frequency tables are displayed in S1 Table):
• Germ cell tumors, trophoblastic tumors, and neoplasms of gonads (Gonadal carcinomas, Malignant gonadal germ cell tumors, Malignant extracranial and
extragonadal germ cell tumors, Intracranial and intraspinal germ cell tumors, Other and unspecified malignant gonadal tumors)
• Other malignant epithelial neoplasms and malignant melanomas (Other and unspecified carcinomas, Skin carcinomas, Malignant melanomas, Nasopharyngeal
carcinomas, Thyroid carcinomas, Adrenocortical carcinomas)
• Langerhans cell histiocytosis
• Hepatic tumors (Hepatic carcinomas, Hepatoblastoma)
• Retinoblastoma
• Other and unspecified malignant neoplasms
5 For specification of chemotherapy variables, see S1 Table.4 Missing in 11 CCS.
5 Missing in 12 CCS.
6 Missing in 19 CCS.
https://doi.org/10.1371/journal.pone.0232708.t001
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Determinants for higher hospitalization rates
Table 2 displays the outcomes of the multivariable model investigating determinants for hospi-
talizations for the five types of underlying diagnoses with the highest RHRs in CCS (Fig 1).
Determinants for endocrine, metabolic and nutritional disorders were female sex (RHR 1.50,
95% CI 1.03–2.17), cranial radiotherapy (RHR: 2.69, 95% CI 1.57–4.63) and abdominopelvic
radiotherapy (RHR: 2.51, 95% CI 1.53–4.13). For hospitalizations for subsequent neoplasms,
determinants were female sex (RHR: 1.80, 95% CI 1.30–2.50), cranial radiotherapy (RHR:
1.85, 95% CI 1.76–2.94), abdominopelvic radiotherapy (RHR: 1.72, 95% CI 1.13–2.63), radio-
therapy to the lower extremities (RHR: 2.04, 95% CI 1.10–3.80) and treatment with epipodo-
phyllotoxins (RHR 1.73, 95% CI 1.06–2.84;Table 2). For hospitalizations for diseases of the
skin and subcutaneous tissue, no treatment related determinants were identified. Cranial
radiotherapy (RHR: 1.74, 95% 1.16–2.59), radiotherapy to the thorax (RHR: 2.94, 95% CI
1.80–4.82) and lower extremities (RHR: 3.79, 95% CI 1.85–7.79) were determinants for hospi-
talizations because of cardiovascular diseases (including ischemic heart disease, cardiovascular
disease, hypertension, and other circulatory disorders), as were treatment with anthracyclines
(RHR: 1.56, 95% CI 1.11–2.19) and alkylating agents (RHR: 1.51, 95% CI 1.05–2.16). Results of
multivariable models for all other types of underlying diagnoses are displayed in S3 Table.
For hospitalizations because of symptoms without an underlying diagnosis, treatment
related risk factors are displayed in Table 2. An additional Poisson regression model, also
including primary cancer diagnosis showed that the risk of hospitalizations for symptoms
without underlying diagnosis was significantly increased for central nervous system tumor
Fig 1. Relative hospitalization rates for five-year childhood cancer survivors as compared to the reference population, overall and for each type of
hospitalization related health condition. Abbreviations: 95% CI: 95% confidence interval, RHR: relative hospitalization ratio.
https://doi.org/10.1371/journal.pone.0232708.g001
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survivors (RHR: 2.95, 95% CI 2.10–4.13), survivors of soft tissue sarcoma (RHR: 1.69, 95% CI
1.11–3.45) and survivors of other tumors (RHR: 2.23, 95% CI 1.51–3.30; S8 Table).
Discussion
This large study, in which a Dutch nationwide cohort of 5,650 long-term CCS and 109,605
matched reference persons were linked to the Dutch Hospital Discharge register, provides
unique detailed insight in the increased risk and determinants of many types of hospitaliza-
tions. An important finding is the high risk of CCS for hospitalizations for symptoms without
an underlying diagnosis.
For this study, we were able to link 92.1% of the nationwide Dutch LATER cohort to an
administrative registry, creating an dataset without selection bias, containing detailed informa-
tion on CCS’s characteristics and their hospitalizations. This large dataset provided sufficient
statistical power for detailed investigation of determinants for 17 types of underlying diagnoses
Fig 2. Relative hospitalization rates for five-year childhood cancer survivors as compared to the reference population, for by childhood cancer
diagnosis.
https://doi.org/10.1371/journal.pone.0232708.g002
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among CCS and for systematical assessment of hospitalizations for symptoms without an
underlying diagnosis. By selecting�20 matched reference persons per CCS, we were able to
relate CCS’s hospitalization rates to the general population. We adjusted for multiple hospitali-
zations within one person, using Generalized Estimated Equations (GEE).
We found that survivors experience significantly increased hospitalization rates, especially
for endocrine conditions, and subsequent neoplasms. These results confirm previous studies,
in which second neoplasms [13–16, 24–26], endocrine conditions [14, 15, 24, 26], conditions
of the blood and blood forming organs [13, 16, 24, 25] and cardiovascular conditions [14, 15,
26] were shown to lead to hospitalizations in CCS. We extended these previous hospitalization
investigations by showing that CCS experienced higher hospitalization rates for nearly all
underlying types of conditions, and by investigating the treatment related determinants for
each type of diagnosis leading to hospitalization in CCS in detail. For hospitalizations for
endocrine, nutritional and metabolic conditions, cranial and abdominopelvic radiotherapy
were treatment related determinants. We hypothesize this can be explained by the high preva-
lence of adrenal conditions, thyroid conditions and other endocrine deficiencies, which can
primary (caused by damage to specific organs) or central (caused by damage to the hypotha-
lamic/pituitary region). These results add important insight to previous literature, in which
only radiotherapy to the head/neck was found to be a determinant for hospitalizations for
endocrine conditions. [26] For hospitalizations because of subsequent neoplasms we identified
cranial, abdominopelvic, and lower extremity radiotherapy and treatment with epipodophyllo-
toxins (which include teniposide and etoposide) as determinants. Although epipodophyllotox-
ins have well-established leukemogenic properties [27, 28]; they were not associated with risk
of subsequent malignant neoplasms in previous analyses in our cohort. [19] We furthermore
found that CCS were nearly three times as likely as the reference population to be hospitalized
because of cardiovascular conditions in comparison to our previous study, we confirmed that
treatment with radiotherapy to the thorax was a determinant, but we identified radiotherapy
to the head as a new determinant. [26] Although radiotherapy to the head was not previously
identified as a risk factor for hospitalization for cardiovascular conditions, previous literature
showed that CCS treated with radiotherapy to the head have an increased risk of stroke. [29–
32] Also, it is suggested that radiotherapy to the head can result in a low growth hormone level
[33], which is likely to contribute to the development of metabolic syndrome [34] and, by
being a modulator of myocardial structure and function [35], is associated with a higher car-
diovascular risk for subgroups of CCS, for example ALL survivors treated with cranial radio-
therapy [36] Moreover, we found that radiotherapy to the lower extremities also was
associated with a higher risk of hospitalizations for cardiovascular conditions, which was not
shown before in literature. We hypothesize this is due to venous diseases, comprising the sec-
ond most prevalent circulatory condition among CCS. The new insights in determinants for
all causes of hospitalizations in CCS as described in this study provide important new leads for
in-depth investigation of determinants for hospitalizations for specific causes. Until now this
knowledge was lacking.
Another important finding in this study is the high risk of hospitalizations for symptoms
without an underlying diagnosis in CCS compared to the reference population, especially in
survivors of central nervous system tumors. We looked in detail into the types of symptoms
for these hospitalizations (S6 Table), and we found that hospitalizations were more often regis-
tered as for ‘other symptoms’ or ‘symptoms unknown’ in CCS than in the reference popula-
tion, implicating that in CCS the underlying cause for hospitalization is often unclear. CCS
might experience clinical symptoms that are unusual for their age range. This, in combination
with their medical history of cancer, might cause clinicians to be more likely to hospitalize
CCS for diagnostic evaluation when there are symptoms without a clear diagnosis. Hence,
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CCS’s medical background can introduce more precautious clinical decision-making. Further-
more, CCS might also have a lower threshold for consulting a physician than individuals who
did not experience cancer as a child. Further research should determine whether a part of
these hospitalizations might be preventable.
A limitation of using data from the LBZ, is that the longitudinal outcome data was available
from 1995 onwards, implicating that data on hospitalizations for the older individuals might
have been missing. This combined with the slight decline in coverage of the LBZ between 2005
and 2013, might have led to an underestimation of the hospitalization rates in both CCS and
reference persons. We have no data that suggests that decline in coverage is higher for certain
types of conditions leading tot hospitalizations. Moreover, there is no reason to assume that
this decline is different for CCS, relative to other groups in the population and therefore, risk
estimates are valid. Also, data on hospitalizations was available from 1995 onwards, which
implicates that for CCS diagnosed in the earlier decades and their corresponding reference
persons, data on hospitalizations in their early follow-up years might be missing. This could
have led to an underestimation of the hospitalization rate in those groups. Because we matched
reference persons for each CCS based on date of diagnosis and age of diagnosis, we expect the
RHR estimates to be valid. Furthermore, since we present the results of many tests of statistical
significance, we caution against over interpretation of our findings, especially those based on P
values exceeding 0.001.
The detailed new knowledge on hospitalizations, causes and determinants in CCS as pre-
sented in this study will support the development of strategies for prevention of excess hospi-
talizations among CCS. This study also provided unique new insights in hospitalizations for
symptoms without an underlying diagnosis and its determinants, thereby providing knowl-
edge on possible preventable hospitalizations among CCS.
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S1 Fig. Flow diagram linking individuals in the Dutch LATER cohort and a selected
matched reference population to the Dutch Hospital Discharge register (LBZ). Abbrevia-
tions: CBS: Statistics Netherlands, CCS: Childhood Cancer Survivors, Dutch LATER: Dutch
Childhood Oncology Group—Long term Effects after Childhood Cancer, LBZ: Dutch Hospital
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the dataset. Because the RIN was also the identifying variable in the Dutch Hospital Discharge
register (LBZ), the RIN was used to link LBZ data to clinical data.
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confidence interval, AER: Absolute Access Risk, CCS: Childhood Cancer Survivors, POP: ref-
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tumors, Intracranial and intraspinal germ cell tumors, Other and unspecified malignant
gonadal tumors)
• Other malignant epithelial neoplasms and malignant melanomas (Other and unspecified
carcinomas, Skin carcinomas, Malignant melanomas, Nasopharyngeal carcinomas, Thyroid
carcinomas, Adrenocortical carcinomas)
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carcinomas, Adrenocortical carcinomas)
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